Sangamo Therapeutics Inc.

There are currently four clinical-stage gene-editing candidates in clinical trials for sickle cell disease, which affects millions of people worldwide...

Clinical Roundup: Gene-Edited Therapies for Beta...

Jul. 26, 2023

In this roundup, we provide a summary of the ongoing gene-editing trials for beta thalassemia. This update includes trials sponsored by Vertex...

Sangamo Therapeutics Inc.

Refractory pain due to small fiber neuropathy (iSFN), (NCT06980948)
Sponsors:
Sangamo Therapeutics

IND Enabling

Phase I

Phase II

Phase III

Human Immunodeficiency Virus Infection, HIV, (NCT04201782)
Sponsors:
Sangamo Therapeutics

IND Enabling

Phase I

Phase II

Phase III

Sickle Cell Disease, SCD, and Transfusion-Dependent Beta-thalassemia, TDT, (NCT05145062)
Sponsors:
Sangamo Therapeutics

IND Enabling

Phase I

Phase II

Phase III

Hemophilia B & Mucopolysaccharidosis, MPS, (NCT04628871)
Sponsors:
Sangamo Therapeutics

IND Enabling

Phase I

Phase II

Phase III

Transfusion-Dependent Beta-Thalassemia, TDT, (NCT03432364)
Sponsors:
Sangamo Therapeutics, Inc.

IND Enabling

Phase I

Phase II

Phase III

Sickle Cell Disease, SCD, (NCT03653247)
Sponsors:
Sangamo Therapeutics

IND Enabling

Phase I

Phase II

Phase III

Human Immunodeficiency Virus Infection, HIV, (NCT02225665)
Sponsors:
Sangamo BioSciences, Inc.

IND Enabling

Phase I

Phase II

Phase III

Mucopolysaccharidosis II, MPS II, (NCT03041324)
Sponsors:
Sangamo Therapeutics Inc.

IND Enabling

Phase I

Phase II

Phase III